Deepanshu Saini, Director of Program Management at IQVIA reflects on the interplay between safety and AI pharmacovigilance.

Live Action alleges "reckless distribution" of the abortion drug mifepristone, urging the Trump administration to suspend its ...

Soon after the FDA’s guidance release, two other major AI announcements also hit the news: Utah began a first-in-the-nation pilot with Doctronic for autonomous AI prescription refills, and OpenAI ...

By Patrick Wingrove Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the ...

A new study co-written by a University of Illinois Urbana-Champaign expert in operations management finds that drugs approved ...

Health care workers are changing how they counsel patients. Experts are using our database to support their research. And ...

A new study published in Therapeutic Innovation & Regulatory Science provides crucial insights into the design and ...

Beware of products claiming to cure cancer on websites or social media platforms, such as Facebook and Instagram. According ...

FDA officials told GAO that competing priorities and an agency reorganization in late 2024 have slowed progress, estimating ...

For companies developing interchangeable biosimilars, the FDA guidance opens the door to more tailored, risk-based programs that may reduce reliance on costly comparative efficacy studies (CES). For ...